<DOC>
	<DOCNO>NCT00290498</DOCNO>
	<brief_summary>The overall goal clinical research study find two different chemotherapy drug combination , R-CHOP R-HCVAD , effective treat B-cell lymphoma . At point , participant assign R-HCVAD arm study . Researchers study safety effectiveness drug combination .</brief_summary>
	<brief_title>Rituximab-HCVAD Patients With B-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>This study originally involve 2 different study drug regimen , R-CHOP R-HCVAD . R-CHOP make rituximab , cyclophosphamide , vincristine , prednisone , common treatment patient non-Hodgkin 's lymphoma . This combination compare R-HCVAD , make rituximab , doxorubicin , cyclophosphamide , vincristine , dexamethasone . Rituximab ( RituxanÂ® ) humanize monoclonal antibody CD20 ( receptor surface malignant B-cell lymphocyte ) . The drug activity aggressive nonaggressive NHL B-cell origin , use combination chemotherapy . Cyclophosphamide type drug know alkylating agent . Vincristine type drug call vinca alkaloid . It typically use lymphoma , leukemia , tumor . Prednisone type steroid . Dexamethasone steroid may activity lymphoma . Methotrexate anti-cancer drug folic acid antagonist . It use treat solid tumor , lymphoma , leukemia , autoimmune disease . When study begin , participant randomly assign ( flip coin ) 1 2 arm : Arm A ( R-HCVAD alternate combination rituximab , methotrexate , Ara-C ) Arm B ( R-CHOP ) . From point , new participant treat Arm A combination , show well . If find eligible take part study , give study drug 21-day cycle . The cycle alternate R-HCVAD combination rituximab , methotrexate , Ara-C. During Cycle 1 ( R-HCVAD cycle ) , receive rituximab needle vein ( intravenously , `` IV '' ) , Day 1 . The infusion take 1 hour . Cyclophosphamide give IV every 12 hour 3 day . Each infusion cyclophosphamide take 3 hour . Doxorubicin give 15-minute infusion Day 5 supervision nurse . Your doctor may also choose give doxorubicin 24-48 hour use small pump carry around waist `` fanny pack . '' You stay hospital receive study drug . Vincristine give IV , Days 5 12 . Each vincristine infusion take hour . Dexamethasone give mouth ( pill , capsule , tablet ) Days 2-5 12-15 . You also give standard medication help prevent possible side effect medication ( nausea , vomit , rash ) . In Cycle 2 ( rituximab-methotrexate-Ara-C cycle ) , receive rituximab Day 1 . You receive methotrexate IV ( finish rituximab ) Days 2 3 . The infusion take 24 hour . You give small `` fanny pack '' pump inside slowly infuse drug . You stay hospital drug give . You give Ara-C every 12 hour Days 3-4 ( total 4 dos ) . You give standard medication help prevent possible side effect medication ( nausea , vomit , rash ) cycle also . Leucovorin give 12 hour methotrexate infusion . It use stop action methotrexate prevent/lessen side effect methotrexate may cause . During treatment , blood draw ( 2-3 tablespoon ) every week routine test . Every 4 week treatment , ask question medical history physical exam check side effect . Every 2 cycle ( every 8 week ) , bone marrow biopsy perform ( positive start study ) , come back negative . You PET scan see tumor respond . Once PET scan come back negative , physician decide need additional PET scan test , . You CT scan chest , abdomen , pelvis , neck every 2 cycle , positive beginning study also . You may additional test do study , physician feel need ( example , need check side effect ) . You may receive additional medication call `` CNS prophylaxis '' receive study treatment . Your doctor discus medication . The `` CNS prophylaxis '' consist alternate dose either doxorubicin methotrexate . The methotrexate give either IV pump `` lumbar puncture '' ( needle insert space vertebra back infuse drug directly spinal area ) . The doxorubicin give IV . Changes dose level CNS prophylaxis approve risk experience serious side effect . You receive study drug 6-8 cycle outpatient basis . This mean admitted hospital receive study drug . You may take study disease get bad . If experience intolerable side effect take study drug , study doctor may decide delay treatment 3 week ( one study cycle ) continue therapy drug low dose . If side effect become severe , doctor may decide take study stop medication . At end schedule treatment , ask return clinic follow-up visit every 6 month first , second , third , fourth year treatment study . You follow every year . If doctor feel necessary , may blood test ( 3-5 teaspoon ) perform visit . You bone marrow biopsy every year first 2 year , positive start study , every year . At visit , ask side effect may experience whether cancer come back . If doctor feel chance cancer come back , may schedule x-ray scan order check . You also ask therapy may treat cancer , come back . If take study reason , ask come back clinic end-of-treatment visit within 4 week last treatment . This visit include physical exam , routine blood test ( 5-8 teaspoon ) , blood-pregnancy test woman able get pregnant , ECG , chest x-ray . This investigational study . All study drug approve FDA treatment lymphoma . Up 66 patient take part study . All patient enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Confirmed diagnosis previously untreated large Bcell Non Hodgkin 's , Large Cell Lymphoma BCell high grade feature . Other aggressive lymphoma Primary Mediastinal large Bcell Lymphomas also allow include . 2 . Patients performance status 02 ( Zubrod Scale ) . 3 . Serum bilirubin &lt; 1.5 mg/dl serum creatinine &lt; 2.0 mg/dl unless due lymphoma ; ANC &gt; 1000/mm^3 platelet &gt; 100,000/mm^3 unless due lymphoma . 4 . Cardiac ejection fraction 50 % great . 5 . Ages 16 60 year ( due fact CHOPR study enough young patient consider standard care ) . 6 . Patients must willing receive transfusion blood product . 7 . Age adjust International Prognostic Index Score 2 8 . Previous steroid allow ( use relieve symptom SVC , etc ) . 1 . Pregnancy ( exclude due teratogenicity involve chemotherapy agent 2 . Positive HIV serology poor tolerance intense chemotherapy regimen 3 . Burkitt 's lymphoma , Mantle cell lymphoma , transform follicular center cell lymphoma , follicular grade III . 4 . Any clinical cytological diagnosis CNS involvement 5 . Any comorbid medical , Child 's Class C liver cirrhosis , endstage renal disease , symptomatic congestive heart failure , psychiatric illness preclude treatment intense dose chemotherapy determine primary investigator . 6 . Concurrent previous malignancy whose prognosis poor ( &lt; 90 % probability survival 5 year ) 7 . Active Hepatitis B C. Chronic carrier Hepatitis B exclude .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>B-Cell Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Hyper-CVAD</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Vincristine</keyword>
	<keyword>R-CHOP</keyword>
	<keyword>R-HCVAD</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
	<keyword>AD</keyword>
	<keyword>Hydroxydaunomycin hydrochloride</keyword>
	<keyword>Neosar</keyword>
</DOC>